• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 5. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890

Introduction to 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID (CAS No. 898766-49-9)

7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID, identified by its Chemical Abstracts Service (CAS) number 898766-49-9, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This compound, featuring a 7-oxoheptanoic acid backbone conjugated with a 2,6-difluorophenyl moiety, exhibits unique structural and functional properties that make it a valuable intermediate in the development of novel therapeutic agents.

The molecular structure of 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID consists of a seven-carbon chain terminated by a carboxylic acid group at one end and an oxo group (ketone) at the other. The presence of the 2,6-difluorophenyl substituent introduces electron-withdrawing effects through the fluorine atoms, which can modulate the reactivity and binding affinity of the molecule. This structural feature is particularly relevant in medicinal chemistry, where such modifications are often employed to enhance metabolic stability, improve pharmacokinetic profiles, and optimize target interactions.

In recent years, there has been growing interest in the development of fluorinated aromatic compounds due to their broad spectrum of biological activities. The 2,6-difluorophenyl group in 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID has been shown to influence both the electronic properties and steric environment of the molecule. This can lead to enhanced binding interactions with biological targets such as enzymes and receptors, making it a promising scaffold for drug discovery.

One of the most compelling aspects of 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID is its utility as a building block in synthetic chemistry. The combination of a reactive ketone group and a stable carboxylic acid moiety allows for diverse functionalization strategies. For instance, the ketone can undergo reduction to form alcohols or further oxidation to esters, while the carboxylic acid can be used to form amides or esters. These transformations make it an invaluable intermediate in constructing more complex molecules.

Recent studies have highlighted the potential applications of this compound in the synthesis of bioactive molecules. For example, researchers have explored its use in developing novel nonsteroidal anti-inflammatory drugs (NSAIDs) and kinase inhibitors. The fluorine atoms in the 2,6-difluorophenyl group contribute to increased lipophilicity and metabolic stability, which are critical factors in drug design. Additionally, the oxo group provides a site for further derivatization, allowing for fine-tuning of pharmacological properties.

The synthesis of 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID typically involves multi-step organic reactions starting from commercially available precursors. Key steps include Friedel-Crafts acylation followed by oxidation and fluorination reactions. Advanced synthetic techniques such as transition metal-catalyzed cross-coupling reactions have also been employed to improve yield and selectivity. These synthetic methodologies underscore the compound's significance as a versatile intermediate in pharmaceutical research.

In addition to its synthetic utility, 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID has been investigated for its potential biological activity. Preliminary studies suggest that derivatives of this compound may exhibit inhibitory effects on certain enzymes involved in inflammatory pathways. The presence of both fluorine atoms and an oxo group creates a unique chemical environment that can interact with biological targets in ways that conventional non-fluorinated compounds cannot. This opens up new avenues for therapeutic intervention.

The growing interest in fluorinated compounds is driven by their ability to modulate drug properties effectively. The electron-withdrawing nature of fluorine atoms can enhance binding affinity by increasing lipophilicity and reducing metabolic degradation. Furthermore, fluorine substitution can influence conformational preferences and electronic distributions within the molecule, leading to improved pharmacological profiles. These advantages make compounds like 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID indispensable tools in modern drug discovery.

From a regulatory perspective, 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID is subject to standard chemical safety protocols due to its reactive functional groups. While it is not classified as a hazardous material under typical conditions, proper handling procedures must be followed to ensure safety during synthesis and application. Researchers working with this compound should adhere to good laboratory practices (GLP) and use appropriate personal protective equipment (PPE).

The future prospects for 7-(2,6-DIFLUOROPHENYL)-7-OXOHEPTANOIC ACID are promising given its versatility and potential applications. As drug discovery efforts continue to evolve, compounds like this will play an increasingly important role in developing next-generation therapeutics. Ongoing research aims to explore new synthetic routes and expand its utility in medicinal chemistry applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)